IMIR (In vivo Molecular Imaging Research group K.U.Leuven)


The IMIR consortium has been selected in June 2010 as a centre of excellence at the K.U.Leuven to obtain programme financing support.

State of the art molecular imaging research expands its impact by implementing additional imaging technologies and by widening the application scope of available imaging technology (e.g. positron emission tomography (PET), magnetic resonance imaging (MRI), bioluminescence imaging).  The latter is achieved by development of specific radiotracers, contrast agents and reporter gene constructs for novel relevant imaging targets and by in vivo validation and imaging research in small animal models of human diseases with the final goal to translate imaging research into the clinic.  Along with this process, image acquisition, processing and analysis is improved. 

The Programme Financing (PF) project ‘IMIR’ aims to develop novel approaches in small animal molecular imaging to advance understanding and monitoring of specific molecular processes related to human diseases.

IMIR research projects are conducted in close collaboration with a large number of peripheral biological and life sciences partners who provide expert information and feedback based on which relevant imaging targets are selected and pursued for in depth preclinical imaging. IMIR aims to provide a stimulating scientific environment for molecular imaging PhD students consisting of state-of-the-art infrastructure of the moSAIC platform and efficient guidance by experienced post-docs and well trained technical staff.
The programme financing is expected to position IMIR within the top preclinical imaging research centers in Europe and will provide substantial leverage effect to downstream clinical research at the K.U.Leuven.